Showing results (991-1000 of 1,787) with videos related to
Sort By:
Pageof 179
Hepatology Communications|July 16, 2019
A Single-Center Experience on Outcomes of Complementary and Alternative Medicine Use Among Patients With CirrhosisCyriac Abby Philips, Rajaguru Paramaguru, Philip Augustine, et al.Hepatology Communications|November 3, 2021
Role of Hepatocyte-Derived Osteopontin in Liver CarcinogenesisRomain Desert, Xiaodong Ge, Zhuolun Song, et al.Hepatology Communications|October 22, 2022
Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASHStephen A Harrison, Patrick R Mayo, Todd M Hobbs, et al.Hepatology Communications|January 29, 2025
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cellsXu Zhou, Wen-Ming Liu, Han-Yong Sun, et al.Hepatology Communications|January 15, 2025
Comparison of clinical outcomes in patients with refractory ascites treated with either TIPS, tunneled peritoneal catheter, or ascites pumpSarah L Schütte, Anja Tiede, Jim B Mauz, et al.Hepatology Communications|January 15, 2025
Duodenal-jejunal bypass ameliorates MASLD in rats by regulating gut microbiota and bile acid metabolism through FXR pathwaysMengting Ren, Yi Xia, Hanghai Pan, et al.Hepatology Communications|January 8, 2025
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationVincent L Chen, Graham F BradyHepatology Communications|January 6, 2025
Spatial mapping of the HCC landscape identifies unique intratumoral perivascular-immune neighborhoodsFelix Marsh-Wakefield, Cositha Santhakumar, Angela L Ferguson, et al.Hepatology Communications|January 8, 2025
Management of primary sclerosing cholangitis: Current state-of-the-artGuilherme Grossi Lopes Cançado, Gideon M HirschfieldPageof 179